BluePrint resource: PCSK9 inhibitor therapies in ACS
BluePrint resource: PCSK9 inhibitor therapies in ACS
Prof. Dr. Anna Franzone, Prof. Dr. Jeanine Roeters van Lennep, Prof. Dr. Uwe Zeymer, Dr. Flavien Vincent, Prof. Dr. Zuzana Motovska
Prof. Dr. Anna Franzone
Cardiologist
Federico II University of Naples
Italy
Prof. Dr. Jeanine Roeters van Lennep
Internist, Vascular Medicine
Erasmus Medical Center
Netherlands
Prof. Dr. Uwe Zeymer
Cardiologist
Heart Center Ludwigshafen
Germany
Dr. Flavien Vincent
Cardiologist
Lille University Hospital
France
Prof. Dr. Zuzana Motovska
Cardiologist
Charles University
Czech Republic
BluePrint Resource | 
10 min
|
Sep 2021
download resources
I agree that this educational programme:
Early (in-hospital) initiation of PCSK9 inhibitor therapy in patients with acute coronary syndrome may provide additional clinical benefit when used on top of statin treatment. This BluePrint describes current recommendations regarding low-density lipoprotein cholesterol targets in patients with ACS, the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the rationale for its inhibition in ACS, and the expected clinical impact of PCSK9 inhibitors in the acute phase of ACS.
Development of this BluePrint was supported by an Independent Educational Grant from Amgen.
CORONARY CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Amgen.
Other programmes of interest
2 min
Other programmes developed by Prof. Dr. Jeanine Roeters van Lennep
Prof. Dr. Jeanine Roeters van Lennep
Internist, Vascular Medicine
Erasmus Medical Center
Netherlands
Other programmes developed by Prof. Dr. Uwe Zeymer
Prof. Dr. Uwe Zeymer
Cardiologist
Heart Center Ludwigshafen
Germany
